Gelteq Limited announced it has entered into a memorandum of understanding with IDT Australia (ASX: IDT) for a dedicated, locally based manufacturing facility. This facility will support the development and scale-up of Gelteq's gel-based products across global pharmaceutical, nutraceutical, and animal health markets.
IDT Australia is recognized for its expertise in pharmaceutical projects and contract manufacturing services, with over 50 years of operation. Their capabilities include cGMP manufacture, high containment, and FDA and TGA approved laboratory testing.
This partnership strategically positions Gelteq to accelerate and scale its products, leveraging IDT's proven development, manufacturing, and regulatory expertise. The agreement is expected to speed up the development of new products targeting these diverse markets, enhancing Gelteq's operational backbone.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.